DURECT Corporation  

(Public, NASDAQ:DRRX)   Watch this stock  
Find more results for DRRX
+0.02 (1.57%)
Apr 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.26 - 1.30
52 week 0.76 - 2.69
Open 1.29
Vol / Avg. 133,060.00/710,766.00
Mkt cap 142.40M
P/E     -
Div/yield     -
EPS -0.22
Shares 110.39M
Beta 1.13
Inst. own 48%
Apr 28, 2014
Q1 2014 DURECT Corporation Earnings Release (Estimated) Add to calendar
Mar 3, 2014
DURECT Corporation at The Wall Street Analyst Investor Conference - Webcast
Feb 27, 2014
Q4 2013 DURECT Corporation Earnings Conference Call - Webcast
Feb 27, 2014
Q4 2013 DURECT Corporation Earnings Release
Feb 13, 2014
DURECT Corporation Conference Call to discuss Approval of POSIDUR by U.S. Food and Drug Administration - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -203.10% 30.53%
Operating margin -192.78% 30.25%
EBITD margin - 32.70%
Return on average assets -70.17% 34.06%
Return on average equity -90.35% 81.39%
Employees 102 -
CDP Score - -


10260 Bubb Road
CUPERTINO, CA 95014-4166
United States - Map
+1-408-7771417 (Phone)
+1-408-7773577 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company�s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company�s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company's developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.

Officers and directors

Felix Theeuwes DSc Chairman of the Board, Chief Scientific Officer
Age: 75
Bio & Compensation  - Reuters
James E. Brown DVM President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Matthew J. Hogan Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Su Il Il Yum Ph.D. Executive Vice President - Pharmaceutical Systems Research and Development
Age: 73
Bio & Compensation  - Reuters
Judy Joice Senior Vice President - Operations and Corporate Quality Assurance
Age: 57
Bio & Compensation  - Reuters
David R. Hoffmann Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Jay P. Shepard Director
Age: 47
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 68
Bio & Compensation  - Reuters
Terrence F. Blaschke M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Armand P. Neukermans Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters